AIM ImmunoTech Achieves Clinical Milestone as Final Subject Receives First Dose in Phase 2 DURIPANC Study in Metastatic Pancreatic Cancer
AIM ImmunoTech said the final subject has received the first dose in its Phase 2 DURIPANC trial of Ampligen (rintatolimod) plus AstraZeneca’s Imfinzi (durvalumab) for metastatic pancreatic cancer. Primary endpoint analysis is expected to start in Dec. 2026, with topline results in Q1 2027; secondary endpoint analysis in June 2027. The primary endpoint is clinical benefit rate at 24 weeks.
First-dose dosing completion in the Phase 2 DURIPANC study moves the program toward endpoint analysis and potential Phase 3 design.
AIM says the final subject received first dose in its Phase 2 DURIPANC trial of Ampligen plus AstraZeneca’s Imfinzi for metastatic pancreatic cancer.
Near-term upside bias as investors price progress toward December 2026 primary endpoint analysis; magnitude likely moderate given Phase 3 is still ahead.
Background
DURIPANC is an investigator-initiated Phase 2 study evaluating AIM’s Ampligen (rintatolimod) with AstraZeneca’s Imfinzi (durvalumab) in metastatic pancreatic cancer, following earlier AIM/Erasmus named patient program signals.
Why it matters
Completing dosing of the final subject is a procedural but meaningful step that sets the schedule for primary endpoint analysis and topline results, which can influence expectations for Phase 3 design and funding/regulatory planning.
Market relevance
Traders can use the disclosed timeline (primary endpoint analysis in Dec 2026; topline in Q1 2027) to frame position management around upcoming clinical catalysts.
Market effects
Supports ongoing investor appetite for immuno-oncology combinations in pancreatic cancer, but does not change the broader sector fundamentals.
Limited; trial is Netherlands-based but the issuer is US-listed and the catalyst is company-specific.
Moderate for oncology R&D sentiment; no direct global policy or competitive read-across is provided.
Alternative perspectives
A dosing milestone without new efficacy/safety data may have limited impact versus the market’s focus on topline clinical benefit and survival outcomes.
The study is single-center and open-label; endpoint definitions (CBR at 24 weeks) may not translate into Phase 3 success, and the article does not address safety signals or enrollment/operational risks beyond dosing completion.
Key entities
- companyAIM ImmunoTech Inc.
Sponsor of Ampligen and the DURIPANC Phase 2 trial; announces final subject first dose and future endpoint timing.
- drugAmpligen (rintatolimod)
AIM’s dsRNA TLR3 agonist immunomodulator being tested in combination in DURIPANC.
- drugImfinzi (durvalumab)
AstraZeneca anti-PD-L1 immune checkpoint inhibitor used in combination with Ampligen.
- clinical_trialDURIPANC
Phase 2 trial in metastatic pancreatic cancer; primary endpoint is Clinical Benefit Rate at 24 weeks.
